Pobrolitide

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 13:25:06 GMT 2025` Edited by `admin` on `Wed Apr 02 13:25:06 GMT 2025`
Protein Type	PEPTIDE
Protein Sub Type
Sequence Origin	SYNTHETIC
Sequence Type	COMPLETE
Record UNII	Q8CK638V28
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Pobrolitide

Common Name

English

Getacatetide

Preferred Name

English

getacatetide [INN]

Common Name

English

D-?-Glutamine, N-acetyl-D-tyrosylglycyl-D-arginyl-D-lysyl-D-lysyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl-D-arginyl-D-arginylglycyl-D-lysyl-D-threonyl-D-leucyl-D-arginyl-D-valyl-D-alanyl-D-lysyl-D-alanyl-D-isoleucyl-D-tyrosyl-D-lysyl-D-arginyl-D-tyros

Common Name

English

N-Acetyl-D-tyrosylglycyl-D-arginyl-D-lysyl-D-lysyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl-D-arginyl-D-arginylglycyl-D-lysyl-D-threonyl-D-leucyl-D-arginyl-D-valyl-D-alanyl-D-lysyl-D-alanyl-D-isoleucyl-D-tyrosyl-D-lysyl-D-arginyl-D-tyrosyl-D-isoleucyl-

Common Name

English

Code System Code Type Description

CAS

2775373-65-2

Created by admin on Wed Apr 02 13:25:06 GMT 2025 , Edited by admin on Wed Apr 02 13:25:06 GMT 2025

PRIMARY

SMS_ID

300000004600

Created by admin on Wed Apr 02 13:25:06 GMT 2025 , Edited by admin on Wed Apr 02 13:25:06 GMT 2025

PRIMARY

NCI_THESAURUS

C203174

Created by admin on Wed Apr 02 13:25:06 GMT 2025 , Edited by admin on Wed Apr 02 13:25:06 GMT 2025

PRIMARY

FDA UNII

Q8CK638V28

Created by admin on Wed Apr 02 13:25:06 GMT 2025 , Edited by admin on Wed Apr 02 13:25:06 GMT 2025

PRIMARY

INN

12817

Created by admin on Wed Apr 02 13:25:06 GMT 2025 , Edited by admin on Wed Apr 02 13:25:06 GMT 2025

PRIMARY

Related Record Type Details


					Q8CK638V28

ACTIVE MOIETY

Comments:

CyPep-1 interacts specifically with neoplastic cells based on their unique electrochemical properties. Assessment of the immune cell composition of tumors following CyPep-1 treatment revealed significant increases in the percentages of CD45+,CD8+, and natural killer (NK) cells, an increased CD8+/Treg cell ratio, and increased percentages of activated CD8+ and NK cells which were positive for PD-1 (LIH_CyPep-1_July 2021). Consistent with an immunomodulatory function, CyPep-1 treatment is synergistic with PD-1 inhibition and exerts an indirect effect on distant non-injected tumors

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO_ACID_SUBSTITUTION	[1_27]				ISOGLUTAMINE, D-	IY2O406N69
AMINO_ACID_SUBSTITUTION	[1_1]	N-TERMINUS			N-ACETYL-D-TYROSINE	ZF9BXD0KPH

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL